title: Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome.
abstract: OBJECTIVE
  To compare the ovulation rate between raloxifene and clomiphene citrate (CC) in patients with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Double-blind, randomized, superiority clinical trial.
  
  
  METHODS
  Tertiary university hospital.
  
  
  METHODS
  Women with ovulatory dysfunction and PCOS based on the Rotterdam criteria.
  
  
  METHODS
  One of two oral treatments: 5 days of 100 mg/day of CC or R.
  
  
  METHODS
  Ovulation, based on follicle collapse on serial ultrasound and midsecretory serum progesterone concentration (≥3 ng/dL).
  
  
  RESULTS
  The women with PCOS (n = 82) were randomized to receive CC (n = 40) or raloxifene (n = 42). From these, 68 patients finished the trial according to the protocol (CC: n = 37; raloxifene: n = 31). There were no statistically significant differences between the groups in ovulation rates per an intention-to-treat analysis based on ultrasound alone (CC: 21 of 40 vs. raloxifene: 17 of 42) or on progesterone levels (CC: 16 of 40 vs. raloxifene: 11 of 42). No serious adverse events were observed in either group.
  
  
  CONCLUSIONS
  No statistically significant difference in ovulation was observed between raloxifene and clomiphene citrate in patients with PCOS with ovulatory dysfunction.
authors.affiliation: Postgraduate Program in Medicine, Ciências Cirúrgicas, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil.
authors.forename: Ernesto
authors.initials: E
authors.lastname: de Paula Guedes Neto
authors.forename: Ricardo Francalacci
authors.initials: RF
authors.lastname: Savaris
authors.forename: Helena
authors.initials: H
authors.lastname: von Eye Corleta
authors.forename: Gisele Silva
authors.initials: GS
authors.lastname: de Moraes
authors.forename: Rafael
authors.initials: R
authors.lastname: do Amaral Cristovam
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Lessey
mesh_terms: D000328:Adult; D002996:Clomiphene / Q000008:administration & dosage* / Q000009:adverse effects; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology; D010060:Ovulation / Q000187:drug effects*; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy*; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
chemical_list: D004965:Estrogen Antagonists; D005300:Fertility Agents, Female; D002996:Clomiphene; D020849:Raloxifene Hydrochloride; D011374:Progesterone